KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer

Journal article

Open access

Peer reviewed

K. Fujiwara, R. Shapira-Frommer, J. Alexandre, B. Monk, T. Fehm, N. Colombo, M.V. Caceres, K. Hasegawa, C. Dubot, J.J. Li, …

Annals of oncology, Vol.30, pp.ix89-ix90

11/2019

Files and links (1)

url

https://doi.org/10.1093/annonc/mdz426.040View

Published (Version of record) Open

1 Record Views

Title: KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Creators: K. Fujiwara - Saitama Medical University
R. Shapira-Frommer - Sheba Medical Center
J. Alexandre - Hôpital Cochin
B. Monk - The US Oncology Network
T. Fehm - Düsseldorf University Hospital
N. Colombo - European Institute of Oncology
M.V. Caceres - Instituto Ángel H Roffo, Roche S.A. Q. e I. - Argentina, Buenos Aires, Buenos Aires, Argentina
K. Hasegawa - Saitama Medical University
C. Dubot - Institute Curie
J.J. Li
K. Stein - MSD
S.M. Keefe - MSD
K. Tewari - University of California, Irvine Medical Center
Publication Details: Annals of oncology, Vol.30, pp.ix89-ix90
Identifiers: 991005969146902656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article